Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute lymphoblastic leukemia recurrent | Phase 1 | CN | 31 May 2024 | |
B-cell lymphoma recurrent | Phase 1 | CN | 31 May 2024 | |
B-cell lymphoma refractory | Phase 1 | CN | 31 May 2024 | |
Refractory T Acute Lymphoblastic Leukemia | Phase 1 | CN | 31 May 2024 | |
B-Cell Lymphoma | Phase 1 | - | - | |
Recurrent B Acute Lymphoblastic Leukemia | IND Approval | CN | 25 Nov 2024 | |
Refractory B Acute Lymphoblastic Leukemia | IND Approval | CN | 25 Nov 2024 |